BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  BioMidwest

  These 3 Gene Therapy Biotechs Could Make Investors Rich

  Immuno-oncology and gene therapy has been a hot field for the last few years, and the approval of the first CAR-T therapies has only set the kindling ablaze.

  October 23, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Lysogene Pushes Forward With Sanfilippo Syndrome Study, Establishes Footprint in U.S.

  Finding a treatment for Sanfilippo Syndrome is a personal matter for the Lysogene team.

  October 23, 2017

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  George Scangos’ Bold Vision

  The former Biogen CEO is making waves at his new venture, Vir Biotechnology.

  October 23, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Biotech Bay

  Shhhh.....There’s a New T-Cell Strategy

  Rumor is there’s a new approach to fighting cancer in town.

  October 23, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Policy

  The IDO Battle Gets Ugly

  Incyte has been at the forefront of the IDO race with its candidate epacadostat.

  October 23, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  FDA

  Alexion Wins Expanded Approval for Blockbuster Drug Soliris

  Alexion is set to secure even more revenue from its blockbuster drug Soliris, the most expensive drug in the world.

  October 23, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  AstraZeneca Gets in on ADC Therapeutics’ Mega $200M Funding Round

  ADC Therapeutics announced it had raised $200M through an oversubscribed private placement.

  October 23, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  DBV Technologies Crashed as Allergy Drug Flunked Phase III Test

  DBV’s share price crumbled over the weekend after its Phase III peanut allergy trial failed to show a statistically significant response against placebo.

  October 23, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Exactech Goes Private in $625M Deal With TPG Capital

  TPG Capital has acquired all the outstanding shares of Exactech common stock for $42 per share.

  October 23, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Amgen’s KYPROLIS Meets Goals in Phase III Multiple Myeloma Study

  A late-stage study shows that a stronger weekly dose of Amgen’s Kyprolis combined with dexamethasone had a greater progression-free survival benefit than a twice-weekly dose of the drug at the approved dosing level.

  October 23, 2017

   · 

  2 min read

   · 

  Alex Keown